Practical guidance on the use of faecal calprotectin

doi:10.1136/flgastro-2016-100762

Review

. 2018 Apr;9(2):87-91.

doi: 10.1136/flgastro-2016-100762. Epub 2017 Feb 22.

Practical guidance on the use of faecal calprotectin

Matthew J Brookes¹, Simon Whitehead², Daniel R Gaya³, Antony Barney Hawthorne⁴

Affiliations

¹ Gastroenterology Department, Royal Wolverhampton NHS Trust, Wolverhampton, UK.
² Department of Clinical Chemistry, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
³ Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
⁴ Department of Medicine, University Hospital of Wales, Cardiff, UK.

PMID: 29588834
PMCID: PMC5868441
DOI: 10.1136/flgastro-2016-100762

Free PMC article

Review

Practical guidance on the use of faecal calprotectin

Matthew J Brookes et al. Frontline Gastroenterol. 2018 Apr.

Free PMC article

. 2018 Apr;9(2):87-91.

doi: 10.1136/flgastro-2016-100762. Epub 2017 Feb 22.

Authors

Matthew J Brookes¹, Simon Whitehead², Daniel R Gaya³, Antony Barney Hawthorne⁴

Affiliations

¹ Gastroenterology Department, Royal Wolverhampton NHS Trust, Wolverhampton, UK.
² Department of Clinical Chemistry, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
³ Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
⁴ Department of Medicine, University Hospital of Wales, Cardiff, UK.

PMID: 29588834
PMCID: PMC5868441
DOI: 10.1136/flgastro-2016-100762

Abstract

Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use. This article reviews the current evidence base around the indications for using biomarkers and their limitations, with a particular focus on faecal calprotectin.

Keywords: CROHN'S DISEASE; IBD; STOOL MARKERS; ULCERATIVE COLITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MJB has received honoraria for advisory board membership to Shield Pharma and Vifor Pharma. He has received grant support from Vifor Pharma. He has been supported for conference expenses by MSD, Vifor, AbbVie, Warner Chilcott and Allergan. None of these was directly related to the preparation of this work. DRG is funded by a Senior NRS Fellowship Award.

Cited by

Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review.
Green Z, Beattie RM, Ashton JJ. Green Z, et al. Transl Pediatr. 2023 Oct 30;12(10):1853-1874. doi: 10.21037/tp-23-210. Epub 2023 Oct 27. Transl Pediatr. 2023. PMID: 37969128 Free PMC article. Review.
S-100 Proteins: Basics and Applications as Biomarkers in Animals with Special Focus on Calgranulins (S100A8, A9, and A12).
Cerón JJ, Ortín-Bustillo A, López-Martínez MJ, Martínez-Subiela S, Eckersall PD, Tecles F, Tvarijonaviciute A, Muñoz-Prieto A. Cerón JJ, et al. Biology (Basel). 2023 Jun 19;12(6):881. doi: 10.3390/biology12060881. Biology (Basel). 2023. PMID: 37372165 Free PMC article. Review.
Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancer.
Pan Z, Lin H, Fu Y, Zeng F, Gu F, Niu G, Fang J, Gu B. Pan Z, et al. Front Immunol. 2023 Jan 19;14:1086898. doi: 10.3389/fimmu.2023.1086898. eCollection 2023. Front Immunol. 2023. PMID: 36742294 Free PMC article.
A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
Gacesa R, Vich Vila A, Collij V, Mujagic Z, Kurilshikov A, Voskuil MD, Festen EAM, Wijmenga C, Jonkers DMAE, Dijkstra G, Fu J, Zhernakova A, Imhann F, Weersma RK. Gacesa R, et al. Gut Microbes. 2021 Jan-Dec;13(1):1943288. doi: 10.1080/19490976.2021.1943288. Gut Microbes. 2021. PMID: 34313538 Free PMC article.
Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis.
Chen ZA, Sun YF, Wang QX, Ma HH, Ma ZZ, Yang CJ. Chen ZA, et al. Front Genet. 2021 Jul 9;12:697514. doi: 10.3389/fgene.2021.697514. eCollection 2021. Front Genet. 2021. PMID: 34306038 Free PMC article.

See all "Cited by" articles

References

1. Mowat C, Cole A, Windsor A, et al. . Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607. doi:10.1136/gut.2010.224154 - DOI - PubMed
1. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterol 2011;140:1817–26. doi:10.1053/j.gastro.2010.11.058 - DOI - PMC - PubMed
1. Menees SB, Powell C, Kurlander J, et al. . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54. doi:10.1038/ajg.2015.6 - DOI - PubMed
1. Van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis 2013;14:62–7. doi:10.1111/1751-2980.12012 - DOI - PubMed
1. Meijer B, Gearry RB, Day A. The role of s100A12 as a systemic marker of inflammation. Int J Inflamm 2012;2012:907078 doi:10.1155/2012/907078 - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Mowat C, Cole A, Windsor A, et al. . Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607. doi:10.1136/gut.2010.224154 - DOI - PubMed

[2] Mowat C, Cole A, Windsor A, et al. . Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607. doi:10.1136/gut.2010.224154 - DOI - PubMed

[3] Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterol 2011;140:1817–26. doi:10.1053/j.gastro.2010.11.058 - DOI - PMC - PubMed

[4] Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterol 2011;140:1817–26. doi:10.1053/j.gastro.2010.11.058 - DOI - PMC - PubMed

[5] Menees SB, Powell C, Kurlander J, et al. . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54. doi:10.1038/ajg.2015.6 - DOI - PubMed

[6] Menees SB, Powell C, Kurlander J, et al. . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54. doi:10.1038/ajg.2015.6 - DOI - PubMed

[7] Van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis 2013;14:62–7. doi:10.1111/1751-2980.12012 - DOI - PubMed

[8] Van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis 2013;14:62–7. doi:10.1111/1751-2980.12012 - DOI - PubMed

[9] Meijer B, Gearry RB, Day A. The role of s100A12 as a systemic marker of inflammation. Int J Inflamm 2012;2012:907078 doi:10.1155/2012/907078 - DOI - PMC - PubMed

[10] Meijer B, Gearry RB, Day A. The role of s100A12 as a systemic marker of inflammation. Int J Inflamm 2012;2012:907078 doi:10.1155/2012/907078 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Practical guidance on the use of faecal calprotectin

Affiliations

Practical guidance on the use of faecal calprotectin

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources